1. Effect of intensive hyperthermia combined with low-dose cisplatin plus radiotherapy in the treatment of patients with locally advanced NSCLC
Luqing CHEN ; Min WANG ; Wanli ZHOU ; Fajun XIANG ; Dejuan HAN ; Zhenyou SUN ; Guowei LIU ; Hongsheng GAO
Chinese Journal of Primary Medicine and Pharmacy 2020;27(3):322-325
Objective:
To investigate the effect and safety of intensive hyperthermia combined with low-dose cisplatin plus radiotherapy in the treatment of patients with locally advanced NSCLC.
Methods:
From January 2012 to December 2015, 104 patients with locally advanced NSCLC were chosen in the Second People's Hospital of Weifang and randomly divided into two groups according to the digital table, with 52 patients in each group.The control group was given low-dose cisplatin plus radiotherapy, and the observation group was given intensive hyperthermia on the basis of control group.The ORR, DCR, median OS, median PFS, KPS score, the levels of coagulation function index and tumor markers before and after treatment and incidence of side effects in the two groups were compared.
Results:
The DCR of the observation group was significantly higher than that of the control group(86.54% vs.69.23%, χ2=8.24,
2.LIX1-like protein promotes liver cancer progression
Jie ZOU ; Xiaoyun ZHU ; Dejuan XIANG ; Yanqiu ZHANG ; Jie LI ; Zhigui SU ; Lingyi KONG ; Hao ZHANG
Acta Pharmaceutica Sinica B 2021;11(6):1578-1591
Limb and CNS expressed 1 like (LIX1L) is over-expressed in several types of tumors. However, the function of LIX1L in glucose metabolism and hepatocellular carcinoma (HCC) progression remains elusive. Here we report that LIX1L is over-expressed in human HCC tissues, which predicts unfavorable prognosis. LIX1L deficiency